Medium-term repeatability for airwave oscillometry in patients with severe asthma taking benralizumab

BackgroundThe effort-independent tidal breathing test used by oscillometry presents a viable alternative for following up patients whose condition is stable while they are receiving biologic therapy.ObjectiveWe aimed to determine intrasession and intersession repeatability values airwave (AOS) spirometry in who were already taking benralizumab.MethodsIn all, 21 with severe eosinophilic asthma attended the Scottish Centre Respiratory Research as part of clinical trial (EudraCT identification number 2019-003763-22). Paired AOS obtained at 3 separate visits (baseline days 28 56) no change therapy.ResultsIntrasession agreement between repeated measurements was excellent (intraclass correlation coefficient ≥ 0.90) all visits. Intersession also 0.80).ConclusionIn this study we report medium-term cohort severely asthmatic benralizumab therapy. Oscillometry can be follow biologics. The We benralizumab. In Intrasession 0.80).